Next Science Limited

NXS

AU0000041329

Pharmaceuticals

Delayed Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.315 ^AUD	-25.00%		-24.10%	-7.35%

Apr. 24	Next Science Product Sales Rise 19% to $5.5 Million for March Quarter	MT
Apr. 24	Transcript : Next Science Limited, Q1 2024 Earnings Call, Apr 24, 2024

Next Science Limited Announces Half Year Report for the Six Months Ended 30 June 2021

August 29, 2021 at 07:17 pm EDT

Next Science Limited announced half year report for the six months ended 30 June 2021. For the period, the company reported revenue of USD 3.9 million. EBIT improved 38% on prior half year.

Latest news about Next Science Limited

Next Science Product Sales Rise 19% to $5.5 Million for March Quarter	Apr. 23	MT
Transcript : Next Science Limited, Q1 2024 Earnings Call, Apr 24, 2024	Apr. 23
Study Showing Benefit from Next Science's XPERIENCE Now Published in Scientific Journal	Apr. 19	MT
Next Science's BLASTX Found to be Efficacious in Treating Pressure Ulcers With Therapy, Says Study	Apr. 09	MT
Next Science Limited Announces Dan Spira, Non-Executive Director, Not Be Seeking Re-Election	Apr. 02	CI
Next Science's Loss Widens in 2023 Despite 89% Revenue Growth; Shares Down 7%	Feb. 27	MT
Next Science Limited Provides Revenue Guidance for the Fiscal Year 2024	Feb. 27	CI
Transcript : Next Science Limited, 2023 Earnings Call, Feb 28, 2024	Feb. 27
Next Science Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Transcript : Next Science Limited - Shareholder/Analyst Call	23-10-24
Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director	23-10-23	CI
Transcript : Next Science Limited, H1 2023 Earnings Call, Aug 31, 2023	23-08-30
Next Science Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Next Science Limited Announces Board Changes	23-08-22	CI
Next Science Limited Announces Change of Registered Office	23-07-06	CI
Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer	23-06-29	CI
Next Science Limited Announces Retirement of Bruce Hancox as Non-Executive Director	23-06-29	CI
Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products	23-06-28	CI
Next Science Appoints Managing Director and CEO; Shares Climb 4%	23-06-15	MT
Next Science Limited Announces Executive Changes	23-06-15	CI
Next Science Limited Announces Executive Changes	23-06-15	CI
Transcript : Next Science Limited - Shareholder/Analyst Call	23-05-25
Next Science Limited(ASX:NXS) dropped from S&P/ASX Emerging Companies Index	23-03-20	CI
Transcript : Next Science Limited, 2022 Earnings Call, Feb 28, 2023	23-02-27
Next Science Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI

Next Science Limited is an Australia-based medical technology company. The Companyâs primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Companyâs products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.

Sector

Pharmaceuticals

Calendar

2024-05-02 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Next Science Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.2044 USD

Average target price

0.2415 USD

Spread / Average Target

+18.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEXT SCIENCE LIMITED	-7.35%	79.39M
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals